Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Colby Thaxton
Northwestern University at Chicago, Department: Urology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Zylem Biosciences, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This project is looking to develop and optimize HDL nanoparticles (NPs) with an organic core (OHDL NPs) with the goal of increasing binding to the esterified cholesterol that underlies atherosclerosis. These OHDL NPs will be refined and tested in a mouse model to evaluate whether the cholesterol binding is effective at reducing plaque burden. Zylem Biosciences has licensed underlying IP related to HDL NPs invented by Thaxton. Consequently, this project looks to potentially improve IP licensed to a company owned by Thaxton, which creates the perception of a conflict of interest that should be managed.
Highly Functional Organic Core Templated High-Density Lipoproteins to Reverse Vascular Disease
PROJECT NARRATIVE Cholesterol loading of macrophages that reside in specific areas of the arterial tree leads to local inflammation and the formation of atherosclerotic plaques. This process worsens with age and can ultimately lead to atherosclerotic cardiovascular disease, which is the leading cause of death in the world. The goal of this proposal is to optimize the synthesis of a functional bio-inspired mimetic of high-density lipoprotein (HDL) using a multifunctional organic core in order to drastically reduce arterial cholesterol and inflammation to eradicate this disease.
Filed on May 21, 2019.
Tell us what you know about Colby Thaxton's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Colby Thaxton filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Colby S. Thaxton | Northwestern University at Chicago | Conflict of Interest | Aurasense, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.